A drug that inhibits viral replication by inducing, viral RNA mutagenesis and is orally administered twice daily for five days.

In a randomized trial, it reduced hospitalization or death by 30% from COVID-19 as compared with placebo.

Available for COVID-19. patients at high risk for progression to severe COVID-19, and within five days of symptoms onset.

Should not be used during pregnancy or in children.

Leave a Reply

Your email address will not be published. Required fields are marked *